logo
logo
Geron Corporation

Geron Corporation

NASDAQ•GERN
CEO: Dr. John A. Scarlett M.D.
セクター: Healthcare
業種: Biotechnology
上場日: 1996-07-31
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
連絡先情報
919 East Hillsdale Boulevard, Suite 250, Foster City, CA, 94404, United States
650-473-7700
www.geron.com
時価総額
$1.04B
PER (TTM)
-13.6
33.3
配当利回り
--
52週高値
$2.84
52週安値
$1.04
52週レンジ
33%
順位56Top 81.7%
2.5
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.5 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$47.23M+67.05%
直近4四半期の推移

EPS

-$0.03-30.83%
直近4四半期の推移

フリーCF

-$13.49M-77.12%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

RYTELO Net Revenue Surges Nine months product revenue reached $135.610M, marking a 368% increase compared to $28.989M in prior year period.
Operating Loss Significantly Narrows Nine months loss from operations improved to $(43.045)M versus $(153.682)M previously, driven by strong revenue uptake.
Strong Liquidity Position Maintained Total cash, equivalents, and marketable securities stood at $421.5M as of September 30, 2025, supporting operations.
Inventory Rises for Sales Total inventory increased to $95.422M by September 30, 2025, up from $38.714M at year-end 2024, supporting commercial supply.

リスク要因

Material Weakness in Controls Material weakness identified in ITGCs related to ERP and payment systems; remediation efforts expected completion by fourth quarter 2025.
RYTELO Commercialization Uncertainty Near-term prospects wholly dependent on RYTELO success; limited experience in commercializing product outside U.S. markets remains a key challenge.
Ongoing Securities Litigation Risk Securities class action and derivative lawsuits pending; outcomes are uncertain and defense costs could require substantial resources.
Debt Covenants Limit Flexibility Pharmakon Loan Agreement imposes operating restrictions; failure to meet covenants could trigger immediate repayment of $125.0M Tranche A debt.

見通し

EU Commercialization Planning Preparing for planned RYTELO commercialization in select EU markets starting in 2026; seeking experienced third parties for launch support.
Increased R&D Spending Expected Expect research and development expenses to increase in Q4 2025 due to ongoing investments supporting CMC strategy and IMpactMF trial completion.
SG&A Expenses Projected Higher Expect selling, general and administrative expenses to increase over remainder of year due to continued investment in RYTELO U.S. commercialization strategy.
Funding Sufficient for Near Term Current cash position, combined with anticipated net revenues from U.S. RYTELO sales, is believed sufficient for projected operating requirements.

同業比較

売上高 (TTM)

Arvinas, Inc.ARVN
$312.30M
+93.9%
Valneva SEVALN
$198.55M
+13.5%
Geron CorporationGERN
$183.40M
+522.1%

粗利益率 (最新四半期)

Arvinas, Inc.ARVN
100.0%
+0.0pp
Arbutus Biopharma CorporationABUS
97.9%
-2.1pp
Day One Biopharmaceuticals, Inc.DAWN
88.7%
-9.6pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
TYRA$1.56B-15.6-35.8%2.0%
SVRA$1.19B-10.9-86.6%21.2%
DAWN$1.13B-7.5-32.1%0.6%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-0.2%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年2月25日
|
EPS:-$0.03
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月7日|
    売上高: $47.23M+67.1%
    |
    EPS: $-0.03-30.8%
    予想通り

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月6日|
    売上高: $49.04M+5459.6%
    |
    EPS: $-0.02-75.4%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月7日|
    売上高: $39.60M+12927.3%
    |
    EPS: $-0.03-67.3%
    予想通り

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月27日|
    売上高: $76.99M+32386.9%
    |
    EPS: $-0.27+15.6%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月7日|
    売上高: $28.27M+17138.4%
    |
    EPS: $-0.04-48.4%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月8日|
    売上高: $882.00K+2941.4%
    |
    EPS: $-0.10+11.2%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月2日|
    売上高: $304.00K+1347.6%
    |
    EPS: $-0.09+31.3%
    予想を下回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月28日|
    売上高: $237.00K-60.2%
    |
    EPS: $-0.32+13.5%
    予想を下回る